EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution

Débora Silva Gonçalves iD, Arn Migowski iD, Susanne Crocamo Ventilari da Costa iD, Rodrigo Saar da Costa iD, Katia Marie Simões E Senna iD, Ivan Ricardo Zimmermann iD

Revista Brasileira de Epidemiologia · 2023

DOI: 10.1590/1980-549720230045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Brasileira de Epidemiologia, 2023. Verfasst von Débora Silva Gonçalves und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Cardiologia, Professional Master's Program in Health Technology Assessment - Rio de Janeiro (RJ), Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To characterize associated factors and overall survival of women with metastatic breast cancer treated with trastuzumab after its incorporation into the SUS, and additionally to present the direct costs of this technology.

Methods

This is a retrospective cohort, based on data from computerized medical records from one of the units of the National Cancer Institute (INCA), in Rio de Janeiro-RJ, Brazil. Women with HER-2 positive metastatic breast cancer undergoing trastuzumab treatment from September 2017 to August 2018 were included. Overall survival was estimated using the Kaplan-Meier method and compared between groups using the log-rank test.

Results

136 women were selected, whose median age at diagnosis was 51 years (range: 21–81 years). The median OS was 43.63 months (95%CI 33.92–53.34). It is observed that the median OS for the population already diagnosed with metastatic disease (stage IV) was significantly lower than for patients diagnosed in stages I-III (37.43 months vs. 48.6 months, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansYoung AdultAdultMiddle AgedAgedAged, 80 and overTrastuzumabRetrospective StudiesErb-b2 Receptor Tyrosine KinasesMastectomyBrazil

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Instituto Nacional de Cardiologia, Professional Master's Program in Health Technology Assessment - Rio de Janeiro (RJ), Brazil.
  • Instituto Nacional do Câncer José Alencar Gomes da Silva - Rio de Janeiro (RJ), Brazil.
  • Universidade de Brasília, School of Health Sciences, Department of Collective Health - Brasília (DF), Brazil.

ORCID-Profile: Débora Silva Gonçalves, Arn Migowski, Susanne Crocamo Ventilari da Costa, Rodrigo Saar da Costa, Katia Marie Simões E Senna, Ivan Ricardo Zimmermann

Zitieren

APA

Gonçalves, D. S., Migowski, A., Costa, S. C. V. D., Costa, R. S. D., Senna, K. M. S. E., & Zimmermann, I. R. (2023). Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution. Revista Brasileira de Epidemiologia. https://doi.org/10.1590/1980-549720230045

Vancouver

Gonçalves DS, Migowski A, Costa SCVD, Costa RSD, Senna KMSE, Zimmermann IR. Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution. Revista Brasileira de Epidemiologia. 2023. doi:10.1590/1980-549720230045

BibTeX
@article{Gonalves2023,
  author = {Gonçalves, Débora Silva and Migowski, Arn and Costa, Susanne Crocamo Ventilari da and Costa, Rodrigo Saar da and Senna, Katia Marie Simões E and Zimmermann, Ivan Ricardo},
  title = {Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution},
  journal = {Revista Brasileira de Epidemiologia},
  year = {2023},
  doi = {10.1590/1980-549720230045}
}
Kostenlos starten →